Etymologia: Cephalosporin by unknown
this variant H3N2 virus. Our findings emphasize the
importance of continued molecular surveillance for char-
acterizing emerging influenza drift variants.  
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cephalosporin
Any of a class of broad-spectrum, relatively penicillinase-resistant, β-lactam antimicrobial drugs
originally derived from species of the fungus Acremonium (formerly called Cephalosporium). Italian
scientist Giuseppe Brotzu first isolated the parent compound cephalosporin C from a sewer in
Sardinia in 1948. Cephalosporins available for medical use today are semisynthetic derivatives of
this natural antimicrobial compound.
Sources: Dorland's illustrated medical dictionary. 30th ed. Philadelphia: Saunders; 2003. and Merriam-Webster's collegiate
dictionary. 11th ed. Springfield (MA): Merriam-Webster's, Inc; 2003.